Show notes at pharmacyjoe.com/episode625.
In this episode, I’ll discuss the recent updates to the IDSA and ACG C diff guidelines.
Critical Care and Hospital Pharmacy Resources for Hospital Pharmacists, PGY-1 Pharmacy Residents, PharmD students, and Preceptors
Show notes at pharmacyjoe.com/episode625.
In this episode, I’ll discuss the recent updates to the IDSA and ACG C diff guidelines.
IDSA changed their first line recommendation to fidaxomicin but the only new data presented were a trial of tapered fidaxomicin (not the regimen for first line) and a phase 3 trial in Japan that failed to meet non-inferiority.
In other words, the only new data for standard rise fidaxomicin was negative and yet they strengthened their recommendation instead of leaving it as an equal option with vancomycin.
Will the insurance industry accept these guidelines such that out of pocket expenses for patients won’t be cost prohibitive. This is the barrier that may make these guidelines moot.